The application for the renewal of the approval of the active substance isofetamid was submitted on 18 September 2023 and the rapporteur Member State has not yet assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and could not provide estimates of when it would be able to submit the draft renewal assessment report to the Commission and the Authority. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 42 months, until 15 March 2030.
Recital 44, Regulation (EU) 2026/1826
In forcesince 28 Jul 2026